Cargando…

Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report

Detalles Bibliográficos
Autores principales:	Cuneo, Antonio, Scarfò, Lydia, Reda, Gianluigi, Varettoni, Marzia, Quaglia, Francesca Maria, Marchetti, Monia, De Paoli, Lorenzo, Re, Francesca, Pietrasanta, Daniela, Rigolin, Gian Matteo, Orsucci, Lorella, Ibatici, Adalberto, Gattei, Valter, Mauro, Francesca R., Trentin, Livio, Laurenti, Luca, Marasca, Roberto, Foà, Robin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2020
Materias:	Letter to Blood
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7414586/ https://www.ncbi.nlm.nih.gov/pubmed/32559271 http://dx.doi.org/10.1182/blood.2020006854

Ejemplares similares

Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study
por: Visentin, Andrea, et al.
Publicado: (2022)

CLL and COVID-19: light at the end of the tunnel?
por: Scarfò, Lydia, et al.
Publicado: (2022)

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus
por: Scarfò, Lydia, et al.
Publicado: (2020)

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
por: Chatzikonstantinou, Thomas, et al.
Publicado: (2021)

Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study
por: Bomben, Riccardo, et al.
Publicado: (2023)

Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study
por: Mauro, Francesca Romana, et al.
Publicado: (2021)

Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab
por: Gentile, Massimo, et al.
Publicado: (2020)

Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group
por: Rigolin, Gian Matteo, et al.
Publicado: (2021)

Vaccination against COVID-19: a challenge in CLL
por: Eichhorst, Barbara
Publicado: (2021)

Boosting BNT162b2 vaccine efficacy in CLL
por: Bhat, Seema A., et al.
Publicado: (2022)

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies
por: Roeker, Lindsey E., et al.
Publicado: (2021)

Curing CLL: one clone at a time
por: Aslan, Burcu, et al.
Publicado: (2022)

Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination
por: Blixt, Lisa, et al.
Publicado: (2022)

Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study
por: Cuneo, Antonio, et al.
Publicado: (2018)

CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL
por: Capasso, Antonella, et al.
Publicado: (2022)

Poster: CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL
por: Capasso, Antonella, et al.
Publicado: (2022)

Premature aging of the immune system affects the response to SARS-CoV-2 mRNA vaccine in β-thalassemia: role of an additional dose
por: Carsetti, Rita, et al.
Publicado: (2022)

First-Line Treatment of Older Patients with CLL: A New Approach in the Chemo-Free Era
por: Urso, Antonio, et al.
Publicado: (2023)

Worldwide Examination of Patients with CLL Hospitalized for COVID-19
por: Roeker, Lindsey E, et al.
Publicado: (2020)

Old and New Drugs for Chronic Lymphocytic Leukemia: Lights and Shadows of Real-World Evidence
por: Marchetti, Monia, et al.
Publicado: (2022)

Aged healthy mice acquire clonal hematopoiesis mutations
por: Chin, Desmond Wai Loon, et al.
Publicado: (2022)

Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?
por: Tedeschi, Alessandra, et al.
Publicado: (2021)

High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 – VERITAS study
por: Mauro, Francesca R., et al.
Publicado: (2023)

P597: XPO1 MUTATIONS IDENTIFY EARLY STAGE CLL CHARACTERIZED BY SHORTER TIME TO FIRST TREATMENT AND ENHANCED BCR SIGNALING
por: Talotta, Donatella, et al.
Publicado: (2023)

Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia
por: Wang, Jiguang, et al.
Publicado: (2014)

Red cell–bound antibodies and transfusion requirements in hospitalized patients with COVID-19
por: Berzuini, Alessandra, et al.
Publicado: (2020)

Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms: An Italian Multicentre Study
por: Visentin, Andrea, et al.
Publicado: (2020)

COVID-19 Pandemic Impact on Chronic Lymphocytic Leukemia (CLL) Patients' Preferences Towards Therapies: The Italian Experience (CHOICE Study)
por: Molica, Stefano, et al.
Publicado: (2021)

Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL
por: Antic, Darko, et al.
Publicado: (2022)

Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL
por: Antic, Darko, et al.
Publicado: (2022)

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
por: Bonfiglio, Silvia, et al.
Publicado: (2023)

Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3
por: Agnoletto, Chiara, et al.
Publicado: (2014)

P608: THE EXPRESSION OF CYTOR LNCRNA HAS POOR PROGNOSTIC VALUE IN CLL PATIENTS AND IS ASSOCIATED WITH MICROENVIRONMENTAL STIMULI.
por: Hernández, Lluís, et al.
Publicado: (2023)

Performance characteristics of a novel blood bag in-line closure device and subsequent product quality assessment
por: Serrano, Katherine, et al.
Publicado: (2010)

Failure of self-disclosure of deferrable risk behaviors associated with transfusion-transmissible infections in blood donors
por: Wong, Horas Tze Hoo, et al.
Publicado: (2015)

Detection, characterization, and enrollment of donors of Ebola convalescent plasma in Sierra Leone
por: Tedder, Richard S., et al.
Publicado: (2018)

Estimation of the number of blood donors during the COVID‐19 incubation period across China and analysis of prevention and control measures for blood transfusion transmission
por: Yuan, Zhaohu, et al.
Publicado: (2020)

Deferral rate variability in blood donor eligibility assessment
por: de Kort, Wim, et al.
Publicado: (2018)

Ensuring HLA‐matched platelet support requires an ethnic diverse donor population
por: Kreuger, Aukje L., et al.
Publicado: (2020)

First results of a ferritin‐based blood donor deferral policy in the Netherlands
por: Vinkenoog, Marieke, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dc44lg4013v5lek06iag20pqeg